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Haemophilus influenzae can cause a variety of invasive diseases
in children. These infections are responsible for sequelae [1]
and important mortality [2–4]. Resistance of H. influenzae to a
variety of antimicrobial agents has been reported with increasing
frequency in recent years [5,6], although in countries where
vaccination against H. influenzae serotype b has been intro-
duced, an important decline in the incidence of invasive disease
has been noticed [7,8].
Recommendations for vaccination policies and antibiotic
treatment must be guided by local epidemiology. Recent data
on invasive infections of H. influenzae in Africa are very rare.
The aim of this study was to determinate the serotype, biotype
and the levels of antibiotic resistance of H. influenzae respon-
sible for invasive disease at the Casablanca IbnRochd University
hospital over a period of 2.5 years.
From June 1994 to December 1996, 117 strains of H.
influenzae were isolated from children aged 0–15 years with
invasive disease, who were admitted to the Ibn Rochd Uni-
versity Hospital of Casablanca. Among the 117 strains, 109
were serotyped, 112 were biotyped, 115 were tested for beta-
lactamase production and 85 were tested for their susceptibilities
to cefotaxime, chloramphenicol, erythromycin and rifampin.
Serotyping was carried out by testing the supernatant of a
broth culture in tryptic soy broth supplemented with Fields
Enrichment (BBL) by countercurrent-immuno-electrophoresis
with polyvalent and monovalent antisera (Difco Laboratories,
Detroit, MI, USA). Biotype was determined by the study of
ornithine decarboxylase and indole production and urea util-
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ization with the API 10 s system (BioMerieux, Narcy L’etoile,
France) or Rosco tablets and urea indole medium (Sanofi-
Pasteur, Marnes La Coquette, France). Beta-lactamase pro-
duction was detected with a nitrocefin-impregnated disc (Carr
Scarborough Microbiologicals, Decatur, Georgia, USA). Qual-
ity control for betalactamase production was carried out with
Staphylococcus aureus ATCC 29213. The minimum inhibitory
concentrations were determined on Mueller–Hinton chocolate
agar by the agar dilution method with an inoculum of 104 CFU
per spot. The breakpoints used were those recommended by
the National Committee for Clinical Laboratory Standards [9].
H. influenzae ATCC 49247 was used as quality control. Data
entry and analysis were carried out using Epi Info 5 (WHO).
From the 117 isolates of H. influenzae responsible for invasive
disease, 74.4% were recovered from cerebrospinal fluid. The
other sites were blood (16.2%), articular fluid (6.8%) and res-
piratory tract specimens (2.6%). These infections were caused
mainly by serotype b (99.1%). The nontypable isolates were
rare in our series; only one case was isolated from articular fluid.
The age of the patients was available for 113 children and 89.3%
occurred in children that were less than 2 years of age (Figure
1). In our series, all biotypes could be responsible for invasive
diseases in children, but at a different magnitudes: biotype I
(57.1%), II (13.4%), VII (9.8%), VI (5.3%), VIII (5.4%), IV
(3.6%), III (4.5%) and V (0.9%). Three isolates (2.6%) produced
a beta-lactamase. These strains belonged to serotype b, and
were responsible for meningitis. One of these strains was also
resistant to chloramphenicol, although chloramphenicol was
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Figure 1 Percentage of cases according to age (n = 113)
still highly active (97.8%). Intermediate resistance (MIC 0.5
4 mg/L) or resistance to erythromycin (MIC  4 mg/L) was
found in 85.9% of the isolates. No isolate was resistant to
parenteral third-generation cephalosporins. Intermediate resist-
ance to rifampin was found at a low rate (3.5%).
The exact incidence of invasive H. influenzae disease in Cas-
ablanca, cannot be determined by this study, because other
children could have been hospitalized in other hospitals. One
important result was that most of our cases occurred in children
under the age of 2 years. This feature is similar to the results
reported in developing countries where H. influenzae infections
occur earlier than in industrialized nations [1,3,7]. The pre-
dominance of serotype b in children has already been reported
in other countries [1,8,10] and had major implication for the
vaccine formulation. The predominance of biotype I is in
accordance with the findings of other authors [10]. The very
low percentage of betalactamase producers reported here is in
contrast with other reports [4–6]. In Morocco, a ‘conference
de consensus’, organized in 1996 [11], was based in part on
these results. Its recommendations were that amoxicillin should
be the first choice for children suffering from meningitis (neo-
nates excluded). The wide variations of the percentages of
betalactamase producers depending on geographical location
[4–6,12] stress the need for local data to provide recom-
mendations for antibiotic treatment. The incidence of multi-
resistant strains (mainly to ampicillin and chloramphenicol) is
usually low [10], but it is important to monitor.
Although these results do not represent all the invasive cases
of H. influenzae in Casablanca during the period of the study,
they are a baseline of surveillance for monitoring the impact of
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vaccination. The number of cases and the age of occurrence of
the disease and the well-documented efficacy of the vaccine
allow us to recommend the introduction of vaccination into
the routine immunization schedule of children in our country.
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